Prescription drug · NDA AUTHORIZED GENERIC
Carisoprodol NDC 51525-5901
Carisoprodol 250 mg/1 · Tablet · Oral · Mylan Pharmaceuticals Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 51525-5901-1 | 51525590101 | 100 TABLET in 1 BOTTLE (51525-5901-1)Marketed from Oct 1, 2016 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Carisoprodol
- Generic name (nonproprietary)
- carisoprodol
- Active ingredients
- Carisoprodol — 250 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Mylan Pharmaceuticals Inc.
- Product type
- Prescription drug
- Marketing category
- NDA authorized genericApplication NDA 011792
- Marketing start
- Listing expires
- DEA schedule
- CIV
- Other FDA classes
- Centrally-mediated Muscle Relaxation (Physiologic effect)
- Identifiers
- Product ID 51525-5901_8c92753a-4b60-4ecf-b411-d66665ae493eSPL ID 8c92753a-4b60-4ecf-b411-d66665ae493eSPL set ID 7c9184c0-7a2e-11df-8c8d-0002a5d5c51bRxCUI 730794UNII 21925K482H
- Pharmacologic class
- Muscle Relaxant
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N451525590101followed by a unit qualifier and the quantityPackage 51525-5901-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Carisoprodol tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use Carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [ see Dosage and Administration (2) ] . Carisoprodol tablets are a muscle relaxant indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. (1) Limitations of Use • Should only be used for acute treatment periods up to two or three wee…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 011792
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.